Investment opportunities

Young biotech companies generally have restricted financial resources at the early stage and look to secure funding rounds by venture capital. Funding has become increasingly difficult to secure and expensive for biotechnology companies.

Some of the Institut Pasteur spin-offs currently welcome funds from business angels, venture capital or corporate venture funds.







Created in 2010, Axenis is a company providing preclinical research services. After more than 15 years of research and development at the Institut Pasteur, Erwan Corcuff, the CEO, offers its know-how and unique models for the realization of industrial preclinical studies.

Contact: Erwan Corcuff, CEO:

Pierre Langlade-Demoyen, the CEO, created Invectys, a company developing vaccines against cancer, in 2010. The company's  main product is a vaccine targeting telomerase protein that is involved in the immortalization of cancer cells.

Contact: Pierre Langlade-Demoyen, the CEO :

Created in 2010, Pathoquest SAS is a distinctive new generation Molecular Diagnostics company that offers a game changing approach using the combination of disruptive NGS (Next Generation Sequencing) and Bioinformatics / Database tools. Luc Boblet is the CEO

Contact: Luc Boblet, CEO:

Created in 2005, THERAVECTYS is a development-stage biotechnology company with a novel vaccine platform that can be applied to the treatment and prevention of a broad range of infectious diseases, cancers, and other diseases and conditions. Research and development activities are based on 15 years of research conducted at the Pasteur Molecular Virology and Vectorology laboratories. Renault Vaillant is the CEO.

Contact: Renault Vaillant, CEO:


Updated on 17/02/2014


Contact & address

Business Development

Technology Transfer & Entrepreneurship Office

Email : 

Institut Pasteur

28 rue du Docteur Roux

75724 Paris Cedex 15 – France